WO2000072023A3 - Diagnosis and treatment of atherosclerosis and coronary heart disease - Google Patents

Diagnosis and treatment of atherosclerosis and coronary heart disease Download PDF

Info

Publication number
WO2000072023A3
WO2000072023A3 PCT/IB2000/000688 IB0000688W WO0072023A3 WO 2000072023 A3 WO2000072023 A3 WO 2000072023A3 IB 0000688 W IB0000688 W IB 0000688W WO 0072023 A3 WO0072023 A3 WO 0072023A3
Authority
WO
WIPO (PCT)
Prior art keywords
atherosclerosis
diagnosis
treatment
heart disease
coronary heart
Prior art date
Application number
PCT/IB2000/000688
Other languages
French (fr)
Other versions
WO2000072023A2 (en
Inventor
Mahavir Singh
Zoltan Prohaszka
Gyorgy Fust
Laszlo Romics
Original Assignee
Semmelweis University Of Medic
Mahavir Singh
Zoltan Prohaszka
Gyorgy Fust
Laszlo Romics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semmelweis University Of Medic, Mahavir Singh, Zoltan Prohaszka, Gyorgy Fust, Laszlo Romics filed Critical Semmelweis University Of Medic
Priority to JP2000620360A priority Critical patent/JP2003502289A/en
Priority to EP00927636A priority patent/EP1179182A2/en
Priority to AU46025/00A priority patent/AU4602500A/en
Priority to KR1020017014790A priority patent/KR20020022669A/en
Priority to CA002373285A priority patent/CA2373285A1/en
Priority to BR0010741-7A priority patent/BR0010741A/en
Publication of WO2000072023A2 publication Critical patent/WO2000072023A2/en
Publication of WO2000072023A3 publication Critical patent/WO2000072023A3/en
Priority to NO20015653A priority patent/NO20015653L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

The present invention concerns novel uses for human HSP60 in methods of treatment or diagnosis of the human body, more particularly diagnostic test methods, the manufacture of diagnostic tests, and diagnostic test kits for patients with vascular disorders due to atherosclerosis, having a tendency to heat shock protein-induced complement activation, for example to myocardial disorders such as coronary heart disease.
PCT/IB2000/000688 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease WO2000072023A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2000620360A JP2003502289A (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
EP00927636A EP1179182A2 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
AU46025/00A AU4602500A (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
KR1020017014790A KR20020022669A (en) 1999-05-21 2000-05-22 Diagnosis and Treatment of Atherosclerosis and Coronary Heart Disease
CA002373285A CA2373285A1 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease
BR0010741-7A BR0010741A (en) 1999-05-21 2000-05-22 hhsp60 or an immunogenic fragment thereof, diagnostic test method for a tendency to complement activation induced by heat shock protein, uses of hhsp60 and a member of the hsp60 protein family, other than hhsp60, and of antigen presenting an epitope unique for hhsp60 and that does not have any shared hsp60 epitopes, diagnostic test kit for patients who have a tendency to complement activation induced by heat shock protein, and methods of manufacturing a drug for the treatment of induced complement activation by heat shock protein, and to identify a compound or substance or agent that inhibits hhsp60-induced complement activation
NO20015653A NO20015653L (en) 1999-05-21 2001-11-20 Diagnosis and treatment of atherosclerosis and coronary heart disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911772.3A GB9911772D0 (en) 1999-05-21 1999-05-21 Diagnosis and treatment of atherosclerosis
GB9911772.3 1999-05-21

Publications (2)

Publication Number Publication Date
WO2000072023A2 WO2000072023A2 (en) 2000-11-30
WO2000072023A3 true WO2000072023A3 (en) 2001-04-05

Family

ID=10853840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000688 WO2000072023A2 (en) 1999-05-21 2000-05-22 Diagnosis and treatment of atherosclerosis and coronary heart disease

Country Status (13)

Country Link
EP (1) EP1179182A2 (en)
JP (1) JP2003502289A (en)
KR (1) KR20020022669A (en)
CN (1) CN1351713A (en)
AU (1) AU4602500A (en)
BR (1) BR0010741A (en)
CA (1) CA2373285A1 (en)
GB (1) GB9911772D0 (en)
HU (1) HUP0201568A2 (en)
NO (1) NO20015653L (en)
RU (1) RU2001134499A (en)
WO (1) WO2000072023A2 (en)
ZA (1) ZA200109544B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
ES2315034B1 (en) * 2004-07-02 2009-12-30 Laboratorios Indas, S.A. THERMAL SHOCK PROTEIN 27 (HSP-27) AS A CARDIOVASCULAR DISEASE MARKER.
CU23504A1 (en) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech PEPTIDES AND DERIVATIVES APL TYPE OF HSP60 AND PHARMACEUTICAL COMPOSITIONS
JP4283812B2 (en) * 2006-01-06 2009-06-24 財団法人工業技術研究院 Diagnostic method of myasthenia gravis and its kit
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
JP4581094B2 (en) * 2006-12-07 2010-11-17 国立大学法人 岡山大学 Testing method for arteriosclerosis
EP2328911A4 (en) 2008-09-22 2012-03-14 Cedars Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
KR102344948B1 (en) * 2018-09-03 2021-12-28 세종대학교산학협력단 Monoclonal antibody N1-A4 specific to human naive pluripotent stem cells
RU2760539C1 (en) * 2021-02-07 2021-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пензенский государственный университет" Method for screening diagnosis of coronary atherosclerosis using non-invasive ca-biomarker
WO2024017423A1 (en) * 2022-07-22 2024-01-25 Centro De Ingenieria Genética Y Biotecnología Peptide for the treatment of diseases associated with apolipoprotein ai or transthyretin involvement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT398495B (en) * 1992-06-09 1994-12-27 Wick Georg Dr Diagnosis or prognosis of atherosclerosis
WO1998008536A2 (en) * 1996-08-30 1998-03-05 Yeda Research And Development Co. Ltd. Method of reducing the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT398495B (en) * 1992-06-09 1994-12-27 Wick Georg Dr Diagnosis or prognosis of atherosclerosis
WO1998008536A2 (en) * 1996-08-30 1998-03-05 Yeda Research And Development Co. Ltd. Method of reducing the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAYR M ET AL: "Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis.", CIRCULATION, vol. 99, no. 12, 30 March 1999 (1999-03-30), pages 1560 - 1566, XP000971179 *
PROHASZKA Z ET AL: "Antibodies against human heat-shock protein (hsp) 60 and mycobacterial hsp65 differ in their antigen specificity and complement-activating ability.", INTERNATIONAL IMMUNOLOGY, vol. 11, no. 9, September 1999 (1999-09-01), pages 1363 - 1370, XP000971301 *
SCHETT G ET AL: "Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity.", JOURNAL OF CLINICAL INVESTIGATION, vol. 96, no. 6, 1995, pages 2569 - 2577, XP000971181 *

Also Published As

Publication number Publication date
NO20015653D0 (en) 2001-11-20
ZA200109544B (en) 2002-06-20
BR0010741A (en) 2002-02-19
RU2001134499A (en) 2003-08-27
JP2003502289A (en) 2003-01-21
NO20015653L (en) 2002-01-17
CA2373285A1 (en) 2000-11-30
GB9911772D0 (en) 1999-07-21
HUP0201568A2 (en) 2002-08-28
WO2000072023A2 (en) 2000-11-30
KR20020022669A (en) 2002-03-27
EP1179182A2 (en) 2002-02-13
AU4602500A (en) 2000-12-12
CN1351713A (en) 2002-05-29

Similar Documents

Publication Publication Date Title
WO2002038794A3 (en) Cardiovascular disease diagnostic and therapeutic targets
EP2071040A3 (en) Diagnostics and therapeutics for vascular disease
WO2000072023A3 (en) Diagnosis and treatment of atherosclerosis and coronary heart disease
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
WO2002040634A3 (en) Expression miniarrays and uses thereof
CA2403687A1 (en) Surgical articles
DE69632601D1 (en) Heartbeat code-based device for the diagnosis and treatment of cardiac arrhythmia
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
EP1532269A4 (en) 1l1rl-1 as a cardiovascular disease marker and therapeutic target
IS2522B (en) Antibodies for ED-B Fibronectin Boxes, Compositions Containing Them, and Their Use for Diagnosis and Treatment of Tumors and Diseases Associated with Vascular Anatomy
EP1019092A4 (en) Therapeutic and diagnostic tools for impaired glucose tolerance conditions
BRPI0411353A (en) modified corina molecules having surrogate activation sequences and applications thereof
Gollub et al. Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel, placebo-controlled multicenter study
WO2003065871A3 (en) Methods and compositions for treating hematological disorders
WO2000061196A3 (en) Fatty acid analogs for diagnosis of coronary artery disease
JP2000352566A5 (en)
FR2828212B1 (en) METHODS OF DIAGNOSING AND PROGNOSING PARKINSON'S DISEASE
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
DE59510686D1 (en) COMPLEX CONNECTIONS FOR DIAGNOSIS OF VASCULAR DISEASES
Cerrato Understanding the mind/body link.
WO2003053364A3 (en) Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
Merri Static and dynamic analyses of ventricular repolarization duration.
Akiyama et al. Ashman phenomenon of the T wave
Douglas THE USE OF ART IN THE DIAGNOSIS AND TREATMENT OF BODY BOUNDARY DISTURBANCE IN SCHIZOPHRENIA.
WO2003039342A3 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807857.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000927636

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01360/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2373285

Country of ref document: CA

Ref document number: 2373285

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09979489

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 620360

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017014790

Country of ref document: KR

Ref document number: 46025/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000927636

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017014790

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017014790

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000927636

Country of ref document: EP